title: Health-related quality of life outcomes after kidney transplantation.
abstract: With the improvements in short and long term graft and patient survival after renal transplantation over the last two decades Health-Related Quality of Life (HRQL) is becoming an important additional outcome parameter. Global and disease specific instruments are available to evaluate objective and subjective QOL. Among the most popular global tools is the SF-36, examples of disease specific instruments are the Kidney Transplant Questionnaire (KTQ), the Kidney Disease Questionnaire (KDQ) and the Kidney Disease-Quality of Life (KDQOL). It is generally accepted that HRQL improves dramatically after successful renal transplantation compared to patients maintained on dialysis treatment but listed for a transplant. It is less clear however which immunosuppressive regimen confers the best QOL. Only few studies compared the different regimens in terms of QOL outcomes. Although limited in number, these studies seem to favour non-cyclosporine based protocols. The main differences that could be observed between patients on cyclosporine versus tacrolimus or sirolimus therapy concern the domains of appearance and fatigue. This may be explained by two common adverse effects occurring under cyclosporine therapy, gingival hyperplasia and hair growth. Another more frequently occurring side effect under calcineurin inhibitor therapy is tremor, which may favour CNI free protocols. This hypothesis, however, has not been formally evaluated in a randomised trial using HRQL measurements.In summary HRQL is becoming more of an issue after renal transplantation. Whether a specific immunosuppressive protocol is superior to others in terms of HRQL remains to be determined.
authors.affiliation: Departments of Internal Medicine I and III, Division of Oncology, University of Vienna, Austria. Wolfgang.Fiebiger@akh-wien.ac.at
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Fiebiger
authors.forename: Christa
authors.initials: C
authors.lastname: Mitterbauer
authors.forename: Rainer
authors.initials: R
authors.lastname: Oberbauer
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000601:surgery* / Q000628:therapy; D016030:Kidney Transplantation / Q000276:immunology*; D017063:Outcome Assessment, Health Care / Q000379:methods*; D011594:Psychometrics / Q000295:instrumentation; D011788:Quality of Life; D006435:Renal Dialysis; D018434:Sickness Impact Profile; D020123:Sirolimus / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D016559:Tacrolimus / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus; D016559:Tacrolimus